



SYLVIA FEDORUK
CANADIAN CENTRE FOR
NUCLEAR INNOVATION INC.

ANNUAL REPORT

2025-26





TABLE OF CONTENTS

2	TABLE OF CONTENTS
4	YEAR IN REVIEW
6	MESSAGE FROM THE BOARD CHAIR
7	MESSAGE FROM THE EXECUTIVE DIRECTOR
8	HOW A CYCLOTRON WORKS
10	FACILITY OPERATIONS
	SAFETY AND LICENSING
	FDG PRODUCTION AND PATIENT IMPACT
	ISOTOPE PRODUCTION AND FACILITY ACCESS
13	FEATURE STORY: ZIRCONIUM-89 AND LAWSON IMAGING RESEARCH CENTRE
14	PROGRAMS AND RESEARCH DEVELOPMENT
	RESEARCH CHAIRS INITIATIVE
	POSTSECONDARY PARTNERSHIPS
16	RESEARCH PROJECTS
	ANNUAL CALL FOR PROPOSALS
	FUNDED PROJECTS OVERVIEW
17	FEATURE STORY: ADVANCING PANCREATIC CANCER THERAPY
18	CAPITAL PLANNING AND INVESTMENTS
	CAPITAL INVESTMENTS
	SECOND CYCLOTRON PLANNING
	BEAMLINE EXPANSION
19	FEATURE STORY: ACTINEER PARTNERSHIP AND AC-225 EXPANSION
20	ENGAGEMENT AND KNOWLEDGE SHARING
	TOURS
	TALKS AND CONFERENCES
	NUCLEARFACTS SYMPOSIUM

THANK YOU TO OUR PARTNERS





YEAR IN REVIEW

Actinium-225 Production Milestone

Following a successful production in October 2024, the Fedoruk Centre achieved multiple Ac-225 irradiations in 2025-26, including two in a single month. This progress strengthens Saskatchewan's position in developing a reliable supply of this highly sought-after medical isotope for cancer therapy.

Leadership Transition

After six years of leadership, Dr. John Root completed his term as executive director in July 2025. Dr. Jeter Hall joined shortly after, beginning a new chapter for the Fedoruk Centre focused on growth, partnerships, and expanded research impact.

Investment in Research Capacity

In October, 2025, the Government of Saskatchewan, through SaskPower announced a \$3 million investment to the Fedoruk Centre to help establish research chairs at both Saskatchewan Polytechnic and First Nations University of Canada. The investment from SaskPower will strengthen workforce development and integrate Indigenous knowledge into nuclear research and future energy systems.

A Nuclear Innovation Symposium

NuclearFACTS 2025 was held on November 5, 2025 and welcomed its largest audience to date, bringing together researchers, students, and industry representatives to learn about and discuss current and emerging topics in nuclear science.





Strengthening Research and Innovation

Through its annual call for proposals, the Fedoruk Centre funded two new research projects, including a promising pancreatic cancer therapy led by USask researcher, Dr. Ekaterina Dadachova and a study by Dr. Arthur Situm from the University of Regina on the long-term durability of metals in molten salt reactors, which use liquid uranium fuel and could provide high-temperature energy for a variety of industries.

Expanding Facility Capacity and Infrastructure

A \$500,000 CMIE grant, announced in March 2026, supports the addition of a second beamline, enabling increased isotope production capacity. Additional support from Innovation Saskatchewan through a \$1.1M investment will support the addition of new automated drug production equipment and a new power supply for the cyclotron. These investments will allow the Fedoruk Centre to consistently deliver nuclear medicine for Saskatchewan patients.



Enhanced Access for Researchers

A new user access model was developed throughout the fiscal year and announced on April 1, 2026 to reduce financial barriers for academic users and reserve up to 30% of facility capacity for discovery-based research.





MESSAGES



Message from the Board Chair

Dawn Pratt

Interim Chair of the Board of Directors

It is an honour to serve as Interim Chair of the Board of Directors of the Sylvia Fedoruk Canadian Centre for Nuclear Innovation (Fedoruk Centre) and to reflect on the Centre's continued growth, momentum, and evolving role in Saskatchewan.

For me, this work is also deeply personal.

More than twenty-five years ago, I began working in nuclear policy and engagement with First Nations across Canada. From those early experiences, I carried with me a strong hope that one day I would have the opportunity to become more directly involved in the nuclear work taking place here in my home province of Saskatchewan, across the Traditional territories of Indigenous Peoples and the lands covered by Treaties 2, 4, 5, 6, 8 & 10 and the Homeland of the Métis. For me, that connection to place also carries a responsibility to ensure that Indigenous voices, knowledge, relationships, and future generations are part of the conversations shaping Saskatchewan's nuclear future.

For many years, I watched from a distance as the Fedoruk Centre began to take shape and come alive. I saw an organization that creates connections among research, innovation, health, industry,

education, and the broader nuclear community. When I joined the Board of Directors three years ago, those long-held hopes began to take root in a new way.

Serving first as a Board Director and now as Interim Chair has allowed me to contribute to an organization positioned at an important moment in Saskatchewan's future.

The Fedoruk Centre is not only helping advance nuclear research and innovation. It is helping create the conditions for the next generation of highly skilled workers, researchers, health professionals, innovators, and leaders who will shape Saskatchewan's future. The work being done today has the potential to influence scientific discovery, improve patient outcomes, strengthen our province's research capacity, and create opportunities that will extend far beyond our current generation.

As Saskatchewan's nuclear landscape continues to evolve, I believe it is increasingly important that we build a future grounded in collaboration, scientific excellence, meaningful relationships, and the inclusion of diverse perspectives. The opportunities before us are significant, and so is our responsibility to ensure that the benefits of innovation, research, and development reach people and communities throughout the province.

I am grateful to serve alongside an exceptional team of Board Directors who generously contribute their knowledge, experience, and advice. Their leadership, together with the dedication of the Fedoruk Centre team and its many partners, continues to strengthen the Centre and expand what is possible.

Looking ahead, I am excited about what the Fedoruk Centre can become. We are helping build more than research capacity; we are helping build people, opportunities, partnerships, and a foundation for Saskatchewan's next generation of nuclear leaders.

For me, being part of this journey brings together more than twenty-five years of experience with a vision I have carried throughout my career: to help shape a nuclear future for Saskatchewan that is innovative, inclusive and grounded in strong relationships with the Indigenous Peoples whose Traditional territories and Treaty lands we share. As our province enters a new era of nuclear research, medicine, technology and development, I believe leadership must look beyond what we can build to consider how we build it, who is part of the conversation, and how the opportunities we create today will benefit the generations who follow.

I am proud to now have the opportunity to help that vision continue to take root.



Message from the Executive Director

Jeter Hall, Ph.D.

**Fedoruk Centre
Executive Director**


I joined the Fedoruk Centre in July 2025. Since that time, I've been extremely impressed by the expertise and skill of the staff and users. The fiscal year ended with the Fedoruk Centre in a good position to continue expanding impact and supporting a growing cadre of users, both in the academic and industrial communities. The support from USask and Innovation Saskatchewan has been critical to operations and recapitalization of the infrastructure.

I had not worked in the field of nuclear medicine in the past, and after a year of learning the ecosystem I am in awe of both the capability and impact Saskatchewan and Canada are having on the sector. The rise of targeted nuclear therapies in the clinical setting has shown the whole industry that new therapies, such as actinium-based therapies, have a huge potential to improve health care outcomes. I am excited that the Fedoruk Centre is

playing a role both in supporting isotope production as well as supporting the development of new drugs that use those isotopes. I think the next few years could see significant growth in nuclear medicine in Saskatchewan.

Saskatchewan is taking a deep look at the feasibility of nuclear power to achieve the goal of carbon-free energy production by 2050. Nuclear power could help address some of the vulnerabilities in the intermittent production of renewable energy sources in our cold and dark winters. The Fedoruk Centre is looking forward to advancing our partnerships with SaskPower and the post-secondary institutions to support the academic and workforce development required to support the consideration and potential deployment of nuclear power in Saskatchewan.

The next year has a wealth of possibilities in research and development of applied nuclear science and technology in Saskatchewan and Canada. I look forward to working with the passionate community of academic researchers and industrial organizations to maximize our impact on the world.




HOW A CYCLOTRON WORKS

In 2025-26, Royal University Hospital's imaging team completed 3,443 PET-CT scans to support cancer diagnosis and treatment using the radioactive imaging agent, fluorodeoxyglucose (FDG), which is produced six days a week at the Saskatchewan Cyclotron Facility.



1. A CYCLOTRON BEGINS WITH AN "ION SOURCE" WHICH USES HYDROGEN GAS AND CONVERTS IT INTO A PLASMA OF CHARGED PARTICLES.
2. THE CHARGED PARTICLES ARE INJECTED INTO A STRONG MAGNET, WHICH FORCES THEM ALONG A CIRCULAR PATH.



3. AN OSCILLATING HIGH-VOLTAGE FIELD ALTERNATINGLY PUSHES AND PULLS THE PARTICLES TO ACCELERATE THEM TO A DESIRED SPEED AND ENERGY.
4. THE HIGH-SPEED PARTICLES STRIKE A CAREFULLY SELECTED MATERIAL CALLED A TARGET.
5. THE IMPACT CONVERTS A SMALL FRACTION OF THE STABLE TARGET MATERIAL INTO RADIOACTIVE ISOTOPES USED IN MEDICINE AND RESEARCH.
6. THE RADIOACTIVE ISOTOPES ARE SAFELY SEPARATED AND PURIFIED FOR USE IN HOSPITALS AND RESEARCH LABS, LIKE THE INNOVATION WING AT THE SASKATCHEWAN CYCLOTRON FACILITY.
7. MEDICAL ISOTOPES HELP DIAGNOSE DISEASE, GUIDE TREATMENT, AND ADVANCE RESEARCH THAT IMPROVES HEALTH CARE.



FACILITY OPERATIONS

0 REPORTABLE INCIDENTS



33 MINOR SAFETY EVENTS

MAX RADIATION DOSE: **1.81 mSv**
WHICH < 50 mSv CNSC REGULATIONS

EMISSIONS WITHIN REGULATORY LIMITS

Safety and Licensing

Safety is the cornerstone of the Saskatchewan Cyclotron Facility (Facility), which houses a 24 MeV cyclotron facility owned by the University of Saskatchewan (USask) and operated by the Fedoruk Centre. As a Class II nuclear facility, Fedoruk Centre staff maintain the Facility in a competitive state of readiness for clients and the public, ensuring that all operations are rigorously monitored and conducted safely for staff, clients, and the broader community.



Fedoruk Centre staff routinely work in an environmentally controlled clean space, wearing protective cleanroom gear while producing radiopharmaceuticals for use at neighbouring hospitals

Did you know that 50 mSv, the annual regulatory limit for radiation exposure for all nuclear workers, is comparable to about 500 chest X-rays?

During 2025, a primary focus of Facility operations was the scaling of isotope production, particularly actinium-225 (Ac-225). To prepare for the increased production, enhanced monitoring of radon and thoron levels within the cyclotron's vault and exhaust systems was necessary to confirm that all emissions were well within regulatory limits. In anticipation of future increases in activity, a supplied air system was introduced to ensure that staff can safely respond to potential airborne hazards.

As a nuclear facility, the Fedoruk Centre must maintain compliance with the Canadian Nuclear Safety Commission (CNSC), Canada's nuclear regulator. Annual reporting confirmed that staff remained well within the CNSC annual radiation exposure limit of 50 mSv at just 1.81 mSv.

The Fedoruk Centre is licensed under Health Canada and maintains a drug establishment license and must ensure safe pharmaceutical manufacturing practices.

A total of 33 minor safety events, including spills and contamination events, were recorded over the fiscal year. All events remained below reporting thresholds and were used proactively to identify opportunities for process improvement. No non-radiological incidents involving staff resulted in serious injury.

FDG Production and Saskatchewan Patient Impact

The Facility continues to play a vital role in supporting cancer diagnosis across Saskatchewan through the production of fluorodeoxyglucose (FDG), a critical imaging agent for PET-CT scans.

245
FDG DELIVERIES
TO RUH

190
SPLIT-BATCH
DELIVERIES

**MULTIPLE HOSPITALS
SERVED** ACROSS THE PRAIRIES

Over the fiscal year, 245 full FDG deliveries were made to RUH, supplemented by approximately 190 additional 'split-batch' afternoon deliveries. These afternoon batches enabled extended scanning hours, significantly improving patient access and helping to reduce diagnostic wait times in the province.

Did you know? The Fedoruk Centre staff start production for FDG at 4 am so that the first patient at Royal University Hospital (RUH) can be scanned at 8 am.

In late December 2025, a temporary cyclotron outage made production of FDG come to a halt. However, contingency supply arrangements from cyclotrons in neighbouring provinces ensured that approximately 50 per cent of scheduled patients still received PET-CT scans in Saskatoon during this period. Operations recovered within two weeks and an increase in production in the final quarter helped support patient care.

The Facility continues to expand its reach by supplying FDG outside of regional hospitals, including the Western College of Veterinary Medicine on USask campus, and to hospitals in Calgary and Winnipeg.



The Facility houses many instruments used to measure radiological and radiopharmaceutical samples for quality and safety.

Isotope production and Facility access for researchers

The Facility has been bolstering its role as a hub for isotope innovation and applied research, supporting researchers in Saskatchewan and beyond. Over the year, 16 batches of zirconium-89 (Zr-89) were produced and dispatched to research institutions across Canada, including Lawson Imaging Research Centre in Ontario (see page 13).

Additional isotopes, including Ac-225, lutetium-177 (Lu-177), copper-64 (Cu-64) and copper-67 (Cu-67), terbium-161 (Tb-161), indium-111 (In-111), and gallium-68 (Ga-68) were accessed by users, demonstrating the breadth of capacity and knowledge of the Fedoruk Centre staff.

PRODUCTION

- 16 BATCHES OF ZR-89
- AC-225 PRODUCTION MILESTONE
- MULTIPLE ISOTOPES PRODUCED FOR RESEARCH

ACCESS

- INCREASED INDUSTRY USE
- NEW ACADEMIC ACCESS MODEL




Researchers use instruments such as a gamma spectrometer to characterize radiological samples.

A major milestone was achieved in collaboration with Canadian Nuclear Laboratories (CNL), with the identification of critical process parameters required for the routine production of Ac-225. This accomplishment represents a significant step toward establishing a reliable supply chain for this highly sought after medical isotope.

Facility usage trends evolved throughout the year. While early periods showed lower use, demand increased significantly in the final quarter, driven by expanded industrial partnerships and new projects. These included major contributions from organizations such as CNL, Iotron, and emerging partners.

To support long-term sustainability, a revised access model was introduced late in the fiscal year. Academic researchers engaged in discovery-based work now have access through a nominal fee designed to increase overall utilization while ensuring the Facility remains financially self-sustaining.



Dr. Donna Goldhawk, Lawson Research Institute in her lab. (photo: submitted)

Zirconium-89 (Zr-89) and Imaging at the Lawson Research Institute

A growing partnership between the Fedoruk Centre and the Lawson Research Institute is helping researchers in Ontario better understand the human microbiome and explore new approaches to treating infectious disease with medical imaging.

The partnership relies on the supply of (Zr-89), a radioisotope produced at the Facility and supplied to Lawson researchers. With a half-life of more than three days, Zr-89 allows scientists to track biological processes over an extended period, giving researchers a broader window into the complex and constantly changing environment of the human gut.

Led by researcher Dr. Donna Goldhawk (pictured above), the Lawson bacteria imaging group (BIG) has developed methods to label probiotics with Zr-89 and follow their movement in real-time using advanced molecular imaging technologies like hybrid positron emission tomography/magnetic

resonance imaging (PET/MRI). This work is providing new insights into how probiotics interact with naturally occurring gut bacteria, how infections spread, and how emerging treatments such as bacteriophage therapy (phage therapy) might one day reduce reliance on antibiotics.

Advancing this research depends on a reliable supply of high-quality Zr-89. Through the Fedoruk Centre, Lawson has access to a consistent source of the isotope produced in accordance with Health Canada accreditation, supporting the potential for near-future clinical studies with human participants.

The collaboration highlights the Fedoruk Centre's role in enabling research beyond Saskatchewan. By providing a reliable supply of high-quality radioisotopes—something not widely available at other facilities—the Fedoruk Centre supports researchers across Canada who may not otherwise have access to these specialized materials, helping advance discoveries that improve human health.



PROGRAMS AND RESEARCH DEVELOPMENT

2 **RESEARCH
CHAIRS**
IN DEVELOPMENT

The Fedoruk Centre continues to prioritize research development through funding and strong partnerships with Saskatchewan's postsecondary institutions. This year, a major focus has been on advancing research capacity aligned with the province's long-term goal of deploying small modular reactors (SMRs).

In collaboration with SaskPower and the University Network of Excellence in Nuclear Engineering (UNENE), progress has been made toward establishing new research chairs, representing more than \$6 million total in provincial investment through the province's Crown Corporation.

4 **POSTSECONDARY
PARTNERS
ENGAGED**

Announced in October 2025, \$3 million will be allocated to the Fedoruk Centre over six years to establish two nuclear research chairs. One Chair will be based at Saskatchewan Polytechnic and will focus on developing training programs to prepare students for skilled trades and technical careers in the nuclear sector. The second chair will be at the First Nations University of Canada, focusing on research that integrates and supports the use of Indigenous knowledge in the licensing, construction, and operation of nuclear power facilities.

\$3 **MILLION**
IN PROVINCIAL
INVESTMENT

The Global Institute for Energy, Minerals, and Society is coordinating efforts to strengthen collaboration across institutions, with the goal of developing a connected cohort of researchers rather than isolated programs. These investments are expected to encourage further recruitment, including potential expansion of nuclear-focused research positions at USask.

**FOCUS: NUCLEAR
POWER** **FOR A GROWING
PROVINCE**

Existing programs continue to demonstrate impact. Research led by the Fedoruk Centre Chair in Neutron Imaging, Dr. Marcella Berg from the University of Regina, is using neutron imaging to advance agricultural applications, highlighting the broad potential of nuclear technologies beyond energy and healthcare.





RESEARCH PROJECTS

**5 PROPOSALS
RECEIVED**
THROUGH THE ANNUAL
CALL FOR PROPOSALS

**2 PROJECTS
FUNDED**

**208K
FEDORUK
CONTRIBUTION**

**318K TOTAL
PROJECT
VALUE**

The Fedoruk Centre continued to support research and innovation through its annual Call for Proposals, which reinforced its role as a facilitator of nuclear research across Saskatchewan. The 2025 call was released on October 1, with a total budget of \$200k and attracted five submissions from researchers aligned with the Fedoruk Centre's strategic priorities.

Following a formal review process, the Project Advisory Committee met in January 2026 to evaluate and rank proposals based on established criteria. Two projects were selected for funding, representing a combined project value of \$316k, including \$208k in direct funding from the Fedoruk Centre. These projects reflect both the quality of submissions received and the importance of targeted investments in advancing nuclear-related research.

All funded projects are required to present at NuclearFACTS2026. The NuclearFACTS symposium is an annual event that brings together industry experts and the nuclear research community to learn about and explore advancements taking place at the Facility (see page 22 for more on NuclearFACTS2025).

Looking ahead to 2026/27, UNENE and the Fedoruk Centre will issue a joint call for proposals which will focus on nuclear engineering research and development with a budget of \$200k. The first call for proposals will be announced in April 2026.



New funding announced for pancreatic cancer therapy research

A newly funded project announced in January 2026 through the Fedoruk Centre, will explore radioligand therapy as a potential treatment for pancreatic cancer.

Dr. Ekaterina Dadachova of USask's College of Pharmacy and Nutrition, along with her team, has identified Centrin-1, a protein expressed primarily in tumors and the testes, and therefore largely absent from most healthy tissues, as a promising target for directing radioligand therapy to pancreatic cancer cells.

Pancreatic cancer is the third leading cause of cancer death of both men and women behind only lung and colorectal cancer and has a five-year survival rate of less than 10 per cent, making progress in treatment for this cancer critical. This urgency is a key driver of the team's upcoming work.

Radioligand therapy delivers radiation directly to cancer cells by attaching radioactive atoms to molecules that specifically seek out tumors. In this project, researchers will use peptides which are small protein-like molecules to link to radioisotopes. The targeted compounds will be designed specifically to bind to pancreatic cancer cells and deliver radiation to destroy tumors while minimizing damage to surrounding healthy tissues.

If successful, this approach could pave the way for more precise and less harmful treatments for pancreatic cancer.

"Access to the Saskatchewan Cyclotron Facility and its imaging equipment enables our team to carry out this study in a complex experimental model," Said Dadachova. "The Facility provides state-of-the-art conditions that support the wellbeing of research animals, minimizing stress while allowing researchers to study treatment responses."



Dr. Ekaterina Dadachova (fourth from left), with her lab team after a team meeting. (photo: submitted)



CAPITAL PLANNING AND INVESTMENTS

The critical nature of the infrastructure and increasing demand for medical and research isotope production has prompted the Fedoruk Centre to plan for the Facility's next phase of growth.

In 2024, the Fedoruk Centre and USask began exploring options to expand capacity while improving the long-term reliability of the Facility. Early planning includes the addition of a second cyclotron to provide redundant production capacity, along with a second beamline to support growing research and commercial isotope production.

Exploring a Second Cyclotron

The Facility's 24 MeV cyclotron remains the powerhouse of isotope production, supplying FDG for cancer imaging at RUH, supporting research both in Saskatchewan and beyond, and providing backup isotope production to neighbouring provinces.

A comprehensive review of the Facility assets identified 62 priority items requiring repair, replacement, or upgrade over the next five years. The need for renewal was reinforced by a cyclotron outage that temporarily disrupted FDG production for RUH.

To address these risks, the Fedoruk Centre has developed a capital renewal and asset management plan that outlines priority infrastructure investments while minimizing disruptions to day-to-day operations.

A key component of that plan is the addition of a second cyclotron, estimated at approximately \$20 million. A second cyclotron would provide redundant production capacity, significantly improving the reliability and resilience of Saskatchewan's medical isotope supply and reducing the risk of interruptions to critical cancer diagnostic services.

While long-term infrastructure planning continues, partnerships with Isologic and Alberta Health Services provide backup isotope supply during outages, helping ensure patients continue to receive timely diagnostic imaging.

New Drug Manufacturing Equipment Gives the Fedoruk Centre a Boost in Production

Through Support from Innovation Saskatchewan, the Fedoruk Centre was able to invest in new automated drug manufacturing equipment and a new modern power supply for the cyclotron. This crucial investment allows us to continue to provide a reliable service for researchers across the world.



Investing in Research

To support growing demand for advanced isotope production, the Fedoruk Centre progressed plans to expand the Facility through the addition of a second beamline. This investment is closely tied to the scale-up of Ac-225 production.

Current infrastructure includes a single high-power target station, which is expected to reach full capacity as commercial production begins. The addition of a second beamline will enable simultaneous production across multiple target stations, supporting both research and commercial activities while increasing overall facility capacity.



The project achieved key milestones over the reporting period. Required approvals were secured from both USask and CNSC. A funding proposal submitted to CMIE Development Fund for \$500k was successful, enabling the procurement of the second beamline, which was ordered in March 2026 and is scheduled for installation in March 2027.

The Fedoruk Centre continues to pursue additional funding and partnership opportunities to support full implementation, including the associated high-power target station. This expansion is expected to unlock new industrial and research opportunities, as well as generate sustained revenue from isotope production.

Updated User Access Agreement



To better support research and enable discovery, the Fedoruk Centre worked with its Board of Directors, USask's leadership team, and the research community to redesign its user access model, effective April 1, 2026.

The previous fee structure, while helping sustain operations, created barriers for academic users and limited participation in discovery-based research. The updated model intends to address these challenges by reducing financial barriers and encouraging greater use of the Facility.

Under the new approach, 20–30 per cent of Facility capacity is reserved for discovery research, with access provided through a nominal annual fee rather than traditional usage charges. This change is intended to increase academic engagement while making more effective use of available infrastructure.

At the same time, operational costs are supported through external revenue sources, including industrial partnerships, isotope sales, and grants, while fees remain in place for specialized services. These changes align the Facility with leading research institutions across Canada and position the Fedoruk Centre to expand access, increase utilization, and meet growing demand in nuclear science and technology.



COMMUNITY ENGAGEMENT

The Fedoruk Centre staff offer tours at the Facility, both as a way to increase public awareness for high school students, university students, conference attendees, and dignitaries, but also to ensure regulatory compliance is met.

Over the fiscal year, Facility staff held 33 tours with 342 people through the doors. Large groups included a Nobel Prize Symposium Event from a local high school, Rosetown

Central High School, multi-day tours through Canadian School of Nuclear Energy Management school in June, and Canadian Association of Physicists tours also in June.

All in all, interest in Facility tours increased over the reporting period, marking increased interest in Fedoruk Centre offerings.

33 INDEPENDENT
TOURS
THROUGH THE FACILITY

STAFF **9**
ATTENDED
CONFERENCES

3 FEDORUK CENTRE
PARTICIPATED IN 3
EDUCATIONAL EVENTS
LIKE THE AMAZING
BIOTECH RACE AND
HACKATHON

8 PRESENTATIONS
TO INTERNATIONAL
CORPORATIONS

8 PRESENTATIONS
**TO LOCAL
SCHOOLS**

16 MEDIA
MENTIONS

7 TOURS
TO INTERNATIONAL, NATIONAL,
AND PROVINCIAL DIGNITARIES

1 ANNUAL
SYMPOSIUM
WITH OVER 60 GUESTS
ATTENDING IN PERSON
AND ONLINE

Talks and Conferences

Outside of regular operations and Facility tours, Fedoruk Centre staff actively engage with communities through conferences, outreach events, and educational programming. They present at conferences in cities around the world and design hands-on activities for events such as the Amazing BioTech Race during BioTech Week.

In May 2025, Fedoruk Centre staff hosted a booth at the inaugural Saskatchewan Energy and Natural Resources Forum, organized by the Saskatchewan First Nations Energy and Natural Resource Centre of Excellence. The event brought together approximately 250 First Nations youth from the province's 74 First Nations.



Fedoruk Centre Facility General Manager, Dale Schick-Martin, and Polish delegates touring the Facility in December, 2025.



In September 2025, following years of planning, the Institute of Electrical and Electronics Engineers (IEEE) held a dedication ceremony outside the Facility to recognize the pioneering work of Sylvia Fedoruk and her team in delivering some of the world's earliest cancer treatments using a Cobalt-60 radiation therapy machine. The event was attended by a dozen guests from academia and industry with Fedoruk Centre Executive Director, Dr. Jeter Hall, providing opening remarks.



Fedoruk Centre Executive Director, Dr. Jeter Hall, presenting at the IEEE dedication ceremony, commemorating the work Sylvia Fedoruk did to advance cancer therapy in Canada.

NuclearFACTS

As a part of the annual projects program, the Fedoruk Centre hosts an annual one-day symposium, NuclearFACTS, where funded project leaders and their teams can share their findings and engage in conversations with industry leaders throughout the day at the Atrium Building at Innovation Saskatchewan's Research & Technology Park.



NuclearFACTS 2025 was held on November 5, 2025, and held a special panel discussion on the future opportunities in the nuclear fuel cycle. The panel was moderated by Dr. Larkin Mosscrop (Kinectrics) with invited guests, Dr. Steve Livingstone (SaskPower), Leslie McGlip (IMII), Dr. Arthur Situm (University of Regina), and Grant Cherkas (SIMSA).



Dr. Chris Yost,
Vice President Research,
University of Regina

In total, 67 participants joined the event—both in person and online—with most attending on-site. Presentations included a keynote address from the University of Regina's Vice President, Research, Dr. Chris Yost; Dr. Marcella Berg, Dr. Chris Phenix, Dr. Arthur Situm and Zoe Hoyda, Dr. Alaz Munzur, Dr. Gordon Huang, Dr. Monique Mayer, Dr. Ekaterina Dadachova, and Adalina Lopez.



(left to right), Dr. Larkin Mosscrop, Dr. Arthur Situm, and Grant Cherkas during the panel discussion (photo: Dave Stobbe)



Dr. Larkin Mosscrop moderated the panel discussion on future opportunities in the nuclear fuel cycle (photo: Dave Stobbe)



Dr. Marcella Berg, pictured above, presented on her research at the 2025 NuclearFACTS (photo: Dave Stobbe)

fedorukcentre.ca



**Sylvia Fedoruk Canadian Centre
for Nuclear Innovation Inc.**

303-111 Research Drive
Saskatoon, SK, Canada S7N 3R2
Phone: 306-966-3377



The Fedoruk Centre is a research centre of the University of Saskatchewan